ClinicalTrials.gg
Active, not recruitingNCT05952037Updated Oct 20, 2026

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

A Phase 2 interventional study of Sonrotoclax and Zanubrutinib in Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent and Waldenstrom's Macroglobulinemia Refractory, sponsored by BeOne Medicines. Active, not recruiting at 72 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by BeOne Medicines · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines — 3 open to participants now, 5 under way, none of them phase 3. Waldenstrom Macroglobulinemia · BeOne Medicines.

Started
2023
with 1 other
Phase 2
3 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, this one is one of 2 that started in 2023, is one of 3 in phase 2, and was the 9th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

3 of the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.

Read the detailed description

This study will test whether sonrotoclax (BGB-11417) can be used to improve outcomes in participants with Waldenström's Macroglobulinemia (WM) both when used alone in those who have not responded well to conventional treatments and when used in combination with zanubrutinib in those who have not yet received treatment. The main goals of the study are to determine how many participants no longer have evidence of cancer or have some improvement in the signs and symptoms of cancer after treatment, and to determine what adverse events, or side effects, participants might experience.

BCL2 is a key protein involved in cell death, and abnormal levels of BCL2 are associated with many cancers. Blocking the action of BCL2 proteins is a promising approach with potential therapeutic benefits in participants with different types of cancers, including WM. This study will enroll approximately 105 participants. All participants will receive sonrotoclax orally as a tablet.

The study will take place at multiple centers worldwide. The overall time to participate in this study is approximately 5 years.

Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Waldenstrom Macroglobulinemia
  • Waldenstrom's Macroglobulinemia Recurrent
  • Waldenstrom's Macroglobulinemia Refractory

Keywords

  • Waldenström's macroglobulinemia
  • Waldenstrom's Macroglobulinemia Recurrent
  • Waldenstrom's Macroglobulinemia Refractory
  • Lymphoma
  • BGB-11417
  • BCL-2i
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical and definitive histologic diagnosis of WM.
  • Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM).
  • For Cohorts 1-3, or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy.
  • For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis).
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Central nervous system (CNS) involvement by WM.
  • Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.
  • History of other ≤ 2 years before study entry.
  • Uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy that was completed ≤ 14 days before the first dose of the study drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants with R/R disease to both Bruton tyrosine kinase (BTK) inhibitor and anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor will receive sonrotoclax at a standard dose, given orally once daily.

    Drug: Sonrotoclax

  • Experimental
    Cohort 2

    Participants with R/R disease to anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor and were intolerant to BTK inhibitor will receive sonrotoclax at a standard dose, given orally once daily.

    Drug: Sonrotoclax

  • Experimental
    Cohort 3

    Participants with R/R disease to a BTK inhibitor treatment and are unsuitable for chemoimmunotherapy will receive sonrotoclax at a standard dose, given orally once daily.

    Drug: Sonrotoclax

  • Experimental
    Cohort 4

    Participants with previously untreated WM will receive sonrotoclax and zanubrutinib combination therapy for a fixed duration.

    Drug: Sonrotoclax · Drug: Zanubrutinib

Interventions

  • Administered orally as a tablet.

    Also known as: BGB-11417

  • Administered orally as a capsule.

    Also known as: BRUKINSA, BGB-3111

06

What researchers measure

Primary outcomes

  1. Cohort 1: Major Response Rate (MRR)

    MRR is defined as the percentage of participants achieving partial response (PR) or better, as assessed by the Independent Review Committee (IRC) per the 11th International Workshop on Waldenström Macroglobulinemia (IWWM-11) WM response criteria.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Cohorts 2 and 3: MRR as assessed by the IRC

    MRR is defined as the percentage of participants achieving PR or better.

    Time frame: Up to approximately 5 years

  2. All Cohorts: MRR as assessed by the Investigator

    MRR is defined as the percentage of participants achieving PR or better.

    Time frame: Up to approximately 5 years

  3. Cohorts 1, 2, and 3: Duration of Major Response (DoMR) as assessed by the IRC

    DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.

    Time frame: Up to approximately 5 years

  4. All Cohorts: DoMR as assessed by the Investigator

    DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.

    Time frame: Up to approximately 5 years

  5. Cohorts 1, 2, and 3: Complete Response (CR) + Very Good Partial Response (VGPR) as assessed by the IRC

    CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.

    Time frame: Up to approximately 5 years

  6. All Cohorts: CR + VGPR as assessed by the Investigator

    CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.

    Time frame: Up to approximately 5 years

  7. Cohorts 1, 2, and 3: Overall Response Rate (ORR) as assessed by the IRC

    ORR is defined as the percentage of participants with minor response (MR) or better.

    Time frame: Up to approximately 5 years

  8. All cohorts: ORR as assessed by the investigator

    ORR is defined as the percentage of participants with MR or better.

    Time frame: Up to approximately 5 years

  9. Cohorts 1, 2, and 3: Duration of Response (DOR) as assessed by the IRC

    DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.

    Time frame: Up to approximately 5 years

  10. All Cohorts: DOR as assessed by the investigator

    DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.

    Time frame: Up to approximately 5 years

  11. Cohorts 1, 2, and 3: Progression-Free Survival (PFS)

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC and by the investigator.

    Time frame: Up to approximately 5 years

  12. Cohorts 1, 2, and 3: Time to major response as assessed by the IRC

    Time to major response is defined as the time from start of study treatment to the first documentation of major response.

    Time frame: Up to approximately 5 years

  13. All Cohorts: Time to major response as assessed by the investigator

    Time to major response is defined as the time from start of study treatment to the first documentation of major response.

    Time frame: Up to approximately 5 years

  14. Cohorts 1, 2, and 3: Overall Survival (OS)

    OS is defined as the time from first study drug administration to the date of death due to any cause.

    Time frame: Up to approximately 5 years

  15. Cohort 4: Time to next treatment

    Defined as the time from the start of treatment to the start of first subsequent therapy for WM.

    Time frame: Up to approximately 5 years

  16. Number of participants reporting adverse events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory abnormalities, physical examination results, and vital signs.

    Time frame: Up to approximately 5 years

  17. All Cohorts: Change from Baseline in Health-Related Quality of Life (HRQoL): NFLymSI-18 Disease-related Symptoms-Physical and Treatment-Related Side Effects Subscales

    HRQoL based on participant-reported outcomes using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item (NFLymSI-18) Version 4. The questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score.

    Time frame: Baseline and approximately months 7, 13, 19, and 25

07

Study locations

72 sites
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2026, 34 months.

Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 19, 2023
StartActual
Oct 23, 2023
Primary completionActual
Sep 22, 2026
CompletionEst.
Aug 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and date precision
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05952037
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Oct 23, 2023
Primary completion
Sep 22, 2026
Completion
Aug 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion